Drug Profile
Research programme: anti-inflammatory and anti-fibrotic therapeutics - Genfit
Alternative Names: TGFTX4; TGFTX5Latest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator Genfit
- Class Anti-inflammatories; Antifibrotics; Small molecules
- Mechanism of Action Receptor protein-tyrosine kinase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatic fibrosis; Inflammatory bowel diseases
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Hepatic-fibrosis in France
- 28 Nov 2019 No recent reports of development identified for research development in Inflammatory-bowel-diseases in France
- 06 Dec 2018 Preclinical trials in Hepatic fibrosis in France (unspecified route) before December 2018 (Genfit pipeline, December 2018)